|
|
|
Global Health Programmes
In the developing world, diseases that can be prevented, managed or cured cause significant suffering and mortality due to a lack of basic knowledge and inadequate health services. We support activities to tackle these diseases through donations of medicines, financial and practical support.
Lymphatic Filariasis
(Also known as elephantiasis or LF)
GSK is a key member of the Global Alliance to Eliminate Lymphatic Filariasis, a 20 year programme to eliminate the disease caused by a parasite and spread by mosquitoes causing permanent disability by donating our antiparasitic medicine albendazole for over 2 billion treatments.
Malaria
Health communities affected by malaria are supported through on-going research into new malaria medicines, treatments and vaccines with preferential pricing through our community investment activities GSK’s RTS,S –the world’s most advanced malaria vaccine candidate –now in a Phase III clinical trial that includes 11 sites in seven African countries.
Personal Hygiene and Sanitation Education (PHASE)
Established in 1988, PHASE is a low-cost education programme helping to reduce diarrhoea-related disease by encouraging school children to wash their hands in 16 countries such as Bangladesh, Bolivia, Kenya, Peru, Tajikistan, UK and Zambia. We reach more than one million children and their extended families.
|